Skip to main content
Top
Published in: Calcified Tissue International 1/2015

01-01-2015 | Original Research

The Role of Calcium and Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) in Human Osteoclast Formation and Resorption

Authors: X. Cheng, E. S. Hookway, T. Kashima, U. Oppermann, A. Galione, N. A. Athanasou

Published in: Calcified Tissue International | Issue 1/2015

Login to get access

Abstract

Osteoclasts are specialised bone resorbing cells which form by fusion of circulating mononuclear phagocyte precursors. Bone resorption results in the release of large amounts of calcium into the extracellular fluid (ECF), but it is not certain whether changes in extracellular calcium concentration [Ca2+]e influence osteoclast formation and resorption. In this study, we sought to determine the effect of [Ca2+]e and NAADP, a potent calcium mobilising messenger that induces calcium uptake, on human osteoclast formation and resorption. CD14+ human monocytes were cultured with M-CSF and RANKL in the presence of different concentrations of calcium and NAADP and the effect on osteoclast formation and resorption evaluated. We found that the number of TRAP+ multinucleated cells and the extent of lacunar resorption were reduced when there was an increase in extracellular calcium and NAADP. This was associated with a decrease in RANK mRNA expression by CD14+ cells. At high concentrations (20 mM) of [Ca2+]e mature osteoclast resorption activity remained unaltered relative to control cultures. Our findings indicate that osteoclast formation is inhibited by a rise in [Ca2+]e and that RANK expression by mononuclear phagocyte osteoclast precursors is also [Ca2+]e dependent. Changes in NAADP also influence osteoclast formation, suggesting a role for this molecule in calcium handling. Osteoclasts remained capable of lacunar resorption, even at high ECF [Ca2+]e, in keeping with their role in physiological and pathological bone resorption.
Literature
1.
go back to reference Blair HC, Athanasou NA (2004) Recent advances in osteoclast biology and pathological bone resorption. Histol Histopathol 19:189–199PubMed Blair HC, Athanasou NA (2004) Recent advances in osteoclast biology and pathological bone resorption. Histol Histopathol 19:189–199PubMed
4.
go back to reference Salo J, Lehenkari P, Mulari M et al (1997) Removal of osteoclast bone resorption products by transcytosis. Science 276:270–273CrossRefPubMed Salo J, Lehenkari P, Mulari M et al (1997) Removal of osteoclast bone resorption products by transcytosis. Science 276:270–273CrossRefPubMed
5.
go back to reference Lee HC (2004) Multiplicity of Ca2+ messengers and Ca2+ stores: a perspective from cyclic ADP-ribose and NAADP. Curr Mol Med 4:227–237CrossRefPubMed Lee HC (2004) Multiplicity of Ca2+ messengers and Ca2+ stores: a perspective from cyclic ADP-ribose and NAADP. Curr Mol Med 4:227–237CrossRefPubMed
10.
go back to reference Kaji H, Sugimoto T, Kanatani M, Chihara K (1996) High extracellular calcium stimulates osteoclast-like cell formation and bone-resorbing activity in the presence of osteoblastic cells. J Bone Miner Res 11:912–920. doi:10.1002/jbmr.5650110707 CrossRefPubMed Kaji H, Sugimoto T, Kanatani M, Chihara K (1996) High extracellular calcium stimulates osteoclast-like cell formation and bone-resorbing activity in the presence of osteoblastic cells. J Bone Miner Res 11:912–920. doi:10.​1002/​jbmr.​5650110707 CrossRefPubMed
11.
12.
go back to reference Kanatani M, Sugimoto T, Kanzawa M et al (1999) High extracellular calcium inhibits osteoclast-like cell formation by directly acting on the calcium-sensing receptor existing in osteoclast precursor cells. Biochem Biophys Res Commun 261:144–148. doi:10.1006/bbrc.1999.0932 CrossRefPubMed Kanatani M, Sugimoto T, Kanzawa M et al (1999) High extracellular calcium inhibits osteoclast-like cell formation by directly acting on the calcium-sensing receptor existing in osteoclast precursor cells. Biochem Biophys Res Commun 261:144–148. doi:10.​1006/​bbrc.​1999.​0932 CrossRefPubMed
15.
go back to reference Rizzoli R, Bonjour J-P (2006) Physiology of calcium and phosphate homeostasis. In: Seibel MJ, Robins SP, Bilezikian JP (eds) Dynamics of bone and cartilage metabolism, 2nd ed. Academic Press, pp 345–360 Rizzoli R, Bonjour J-P (2006) Physiology of calcium and phosphate homeostasis. In: Seibel MJ, Robins SP, Bilezikian JP (eds) Dynamics of bone and cartilage metabolism, 2nd ed. Academic Press, pp 345–360
16.
18.
24.
go back to reference Sun L, Adebanjo OA, Moonga BS et al (1999) CD38/ADP-ribosyl cyclase: a new role in the regulation of osteoclastic bone resorption. J Cell Biol 146:1161–1172CrossRefPubMedCentralPubMed Sun L, Adebanjo OA, Moonga BS et al (1999) CD38/ADP-ribosyl cyclase: a new role in the regulation of osteoclastic bone resorption. J Cell Biol 146:1161–1172CrossRefPubMedCentralPubMed
Metadata
Title
The Role of Calcium and Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) in Human Osteoclast Formation and Resorption
Authors
X. Cheng
E. S. Hookway
T. Kashima
U. Oppermann
A. Galione
N. A. Athanasou
Publication date
01-01-2015
Publisher
Springer US
Published in
Calcified Tissue International / Issue 1/2015
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-014-9939-3

Other articles of this Issue 1/2015

Calcified Tissue International 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine